Research Progress of HGF/MET Signaling Pathway in EGFR-TKI Resistance in Non-small Cell Lung Cancer
Lung cancer is one of the most common malignant tumors of the world, and non-small cell lung cancer (NSCLC) makes up about 80%. The hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (MET) signal pathway has pleiotropic effects on many biological processes. However, aberrant HGF...
Main Authors: | Shilong SONG, Minghong BI |
---|---|
Format: | Article |
Language: | zho |
Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2014-10-01
|
Series: | Chinese Journal of Lung Cancer |
Subjects: | |
Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2014.10.08 |
Similar Items
-
Research Progress of HGF/c-MET Inhibitor in the Treatment
of Non-small Cell Lung Cancer
by: Tao JIANG, et al.
Published: (2015-04-01) -
A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance
by: Li Liu, et al.
Published: (2021-10-01) -
The role of HGF-MET pathway and CCDC66 cirRNA expression in EGFR resistance and epithelial-to-mesenchymal transition of lung adenocarcinoma cells
by: Nithila A. Joseph, et al.
Published: (2018-05-01) -
c-Met Signaling Pathway Participating in the Gefitinib Resistance of Different Gene Types of Non-small Cell Lung Cancer Cells Induced by HGF In Vitro
by: Xianglan XUAN, et al.
Published: (2013-09-01) -
Clinical Developments for the EGFR-TKI Combined with Radiotherapy in Advanced Non-small Cell Lung Cancer
by: Xianan LI, et al.
Published: (2014-04-01)